Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

TRE VASCULAR, INC (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

For the three months ended

March 31, 2008 March 31, 2007

Net sales $11,847 $9,883

Cost of sales 3,358 2,513

Gross profit 8,489 7,370

Operating expenses:

Sales and marketing 5,829 4,810

General and administrative 2,828 2,370

Research and development 1,350 1,154

Restructuring charges 633 6

Impairment charge 435 7

Total operating expenses 11,075 8,347

Loss from operations (2,586) (977)

Other income (expense):

Interest income (expense), net 161 351

Other income, net 151 25

Total other income, net 312 376

Loss before income taxes (2,274) (601)

Provision for income taxes 290 28

Net loss $(2,564) $(629)

Net loss per share of common stock:

Basic $(0.17
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Global Stem Cells Group.com ... HANK Bioengineering Co., Ltd. and its Chinese-American founder ... a stem cells training course in the City ... , Shenzhen HANK is a biotechnology company established ... and virologist, to integrate research, development, production, and ...
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Tingey, Reading Scientific Services Ltd., The Lord Zuckerman,Research Centre, Whiteknights, PO Box 234, Reading ... Introduction , ... use of genetically , modified organisms (GMOs) ... from consumers, particularly in Europe, for clear labeling of products , ...
... Faye Boeckman, Marni Brisson, and Larissa Tan, Bio-Rad Laboratories, Inc.,Hercules ... , General Information ... proven to be a versatile tool , in ... advances in gene discovery, diagnostics, and gene expression analysis. , ...
... Inc., 2000 Alfred Nobel Drive,Hercules, CA 94547 USA , ... Real-Time PCR , ... , in the technology and associated equipment have ... today relative to earlier protocols. One of the , ...
Cached Biology Technology:The iCycler iQ and Amplifluor Detection Systems for Analysis of Genetically Modified Organisms in Foodstuffs, Rev A 2The iCycler iQ and Amplifluor Detection Systems for Analysis of Genetically Modified Organisms in Foodstuffs, Rev A 3The iCycler iQ and Amplifluor Detection Systems for Analysis of Genetically Modified Organisms in Foodstuffs, Rev A 4The iCycler iQ and Amplifluor Detection Systems for Analysis of Genetically Modified Organisms in Foodstuffs, Rev A 5The iCycler iQ and Amplifluor Detection Systems for Analysis of Genetically Modified Organisms in Foodstuffs, Rev A 6Real-Time PCR: General Considerations, Rev A 2Real-Time PCR: General Considerations, Rev A 3Real-Time PCR: General Considerations, Rev A 4Real-Time PCR: General Considerations, Rev A 5Real-Time PCR: General Considerations, Rev A 6Real-Time PCR: General Considerations, Rev A 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 2The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 4The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 5The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 6The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 8
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... few minutes looking at your child's eye color. ... for. According to Bruno Laeng and colleagues, from ... reflects a simple, predictable and reliable genetic pattern of ... Springer journal Behavioral Ecology and Sociobiology, show that blue-eyed ...
... that furthers our understanding of how hybridization may contribute ... researchers have found that the genomes of three sunflower ... same two parental types have undergone a massive proliferation ... are reported by Mark Ungerer and colleagues at Kansas ...
... mental activity and enhancing mental function can improve ... an effective addition to medications commonly used to ... computer activities were even more successful than classic ... patients. The findings, from the Fundació ACE, Institut ...
Cached Biology News:Blue eyes -- A clue to paternity 2Sunflower speciation highlights roles for transposable elements in evolution 2Computer-based 'games' enhance mental function in patients with Alzheimer's 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... Gasket slide kit (1x 22K gasket/slide) G2534-60003 ... or Gasket slide kit (2x 11K gasket/slide) ... offered in either 11K or 22K microarray feature formats, ... are carefully fabricated and batch tested to ensure performance ...
... design in ice/water bath This CLS ... created to easily match Cornings product ... please order under the old Sigma-Aldrich ... for assistance. ID clarifier: rack and ...
Biology Products: